David Risinger Analyst PerformanceAnalyst at Leerink PartnersDavid Risinger is a stock analyst at Leerink Partners, covering 23 publicly traded companies across a range of sectors. Over the past year, David Risinger has issued 5 stock ratings, including buy and hold recommendations. While full access to David Risinger's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Risinger's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Ratings, Coverage, and Performance StatisticsAnalyst RatingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings144 Last 10 YearsBuy Recommendations41.96% 60 Buy RatingsCompanies Covered23 Unique Companies Ratings Distribution143RatingsDistribution of strong buy, buy, hold, and sell ratings by David Risinger.RatingPercentageCount Strong Buy0.0%0 ratings Buy42.0%60 ratings Hold51.7%74 ratings Sell6.3%9 ratingsOut of 143 total stock ratings issued by David Risinger at Leerink Partners, the majority (51.7%) have been Hold recommendations, followed by 42.0% Buy and 6.3% Sell.Best & Worst CallsBest Call000.0%AGNDec 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BHCJul 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNYSE60.9% of companies on NYSE14 companiesNASDAQ39.1% of companies on NASDAQ9 companiesDavid Risinger, an analyst at Leerink Partners, currently covers 23 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.Coverage FocusSector IconSectorPercentageMedical23 companies100.0%David Risinger of Leerink Partners specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE6 companies26.1%LARGE CAP PHARMA5 companies21.7%PHARMACEUTICAL PREPARATIONS5 companies21.7%MED - GENERIC DRG2 companies8.7%MED PRODUCTS2 companies8.7%MED - DRUGS1 company4.3%MED - OUTP/HM CRE1 company4.3%MEDICAL SERVICES1 company4.3% David Risinger's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMTSRMetsera9/9/2025Initiated Coverage$35.10$77.00Outperform$0.0000.00% ROIJNJJohnson & Johnson5/13/2025Downgrade$153.88$153.00Market Perform$0.0000.00% ROIVRTXVertex Pharmaceuticals5/6/2025Reiterated Rating$500.19$503.00Market Perform$0.0000.00% ROIREGNRegeneron Pharmaceuticals2/5/2025Upgrade$697.05$834.00Outperform$0.0000.00% ROIJNJJohnson & Johnson1/23/2025Lower Price Target$146.81$169.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
